Cited by 174SARS-CoV-2 and COVID-19 ResearchLegal, Health, Environmental and COVID-19 ChallengesVaccine Coverage and Hesitancy

The DOI matches its Crossref record.

Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees

Jiang, Shibo·2020·Nature

DOI 10.1038/d41586-020-00751-9

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1038/d41586-020-00751-9

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 101–174 of 174

Pneumatosis Intestinalis in the Setting of COVID-19: A Single Center Case Series From New York
Miyara, S. J., Becker, L. B., Guevara, S., Kirsch, C., Metz, C. N., Shoaib, M., Grodstein, E., Nair, V. V., Jandovitz, N., McCann-Molmenti, A., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.638075 · Cited by 9
“It should always be cautioned that deleterious interactions between drug-related adverse effects and intrinsic features of an infectious disease, in this case COVID-19, can lead to further complications (77, 78) “Primum non nocere”.”
Background
Vaccine Hesitancy and Secondary Risks
Cummings, C. L., Gopi, S., & Rosenthal, S. (2021) · Risk, systems and decisions · doi:10.1007/978-3-030-77344-1_6 · Cited by 9
COVID-19: What is next for nursing in public health emergency?
Zhang, X., Shi, T., & Sun, L. (2020) · Nurse Education in Practice · doi:10.1016/j.nepr.2020.102821 · Cited by 9
COVID-19 Modified mRNA “Vaccines”: Lessons Learned from Clinical Trials, Mass Vaccination, and the Bio-Pharmaceutical Complex, Part 1
Mead, M. N., Seneff, S., Wolfinger, R. D., Rose, J., Denhaerynck, K., Kirsch, S., & McCullough, P. A. (2024) · International Journal of Vaccine Theory Practice and Research · doi:10.56098/fdrasy50 · Cited by 18
SARS-CoV-2 and the Vaccination Hype
Sangaletti, P., Doe, J., Gatti, A. M., Arvay, C. G., Giuliani, L., & Lettner, H. (2022) · International Journal of Vaccine Theory Practice and Research · doi:10.56098/ijvtpr.v2i1.34 · Cited by 8
“…injections against COVID-19, especially when based on the transduction of nucleic acids (themselves capable of unknown adjuvant-type “side-effects” such as thyroiditis; Pujol et al., 2021), would be a violation of the precautionary principle (Jiang, 2020; Arvay, 2020; Rosenthal and Cummings, 2021).”
Background
Health Preparedness and Narrative Rationality: A Call for Narrative Preparedness
Engebretsen, E., & Baker, M. (2023) · International Journal of Health Policy and Management · doi:10.34172/ijhpm.2023.7532 · Cited by 8
COVID-19 and molecular hydrogen inhalation
Ostojić, S. M. (2020) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466620951051 · Cited by 7
DESIGN OF A SMART PREFABRICATED SANITISING CHAMBER FOR COVID-19 USING COMPUTATIONAL FLUID DYNAMICS
Abu-Zidan, Y., Nguyen, K. T. Q., Mendis, P. A., et al. (2021) · Journal of Civil Engineering and Management · doi:10.3846/jcem.2021.14348 · Cited by 7
“This pandemic, named COVID-19 by the World Health Organisation (WHO), has exposed the unpreparedness of many countries in dealing with disease outbreaks (Jiang, 2020), highlighting the need to develop systems and tools to improve response to outbreaks of highly contagious diseases such as COVID-19 and others that may…”
Background
CURRENT UPDATES ON COVID-19 VACCINES
Misra, S. K., Pathak, K., Pathak, D., et al. (2021) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2021.v14i5.41061 · Cited by 7
“The developed effective COVID-19 vaccine need to address such issues to control current pandemic, its reoccurrence, and future epidemics [46].”
Background
22-Hydroxyhopane, a novel multitargeted phytocompound against SARS-CoV-2 from Adiantum latifolium Lam
Kumar, R. P., & Siddique, S. (2021) · Natural Product Research · doi:10.1080/14786419.2021.1976177 · Cited by 6
“The SARS-CoV-2 mutates faster and therefore previously effective antivirals might become ineffective (Jiang 2020).”
Background
Genetische Impfstoffe gegen COVID-19: Hoffnung oder Risiko
Arvay, C. G. (2020) · Bulletin des Médecins Suisses · doi:10.4414/saez.2020.18982 · Cited by 6
Knowledge, Attitudes, Behavior, Acceptance, and Hesitancy in Relation to the COVID-19 Vaccine among Pregnant and Breastfeeding Women: A Systematic Review Protocol
Gianfredi, V., Berti, A., D’Amico, M., Lorenzo, V. D., & Castaldi, S. (2023) · Women · doi:10.3390/women3010006 · Cited by 5
Design Considerations for Vaccine Trials with a Special Focus on COVID-19 Vaccine Development
Chen, J., & Ting, N. (2021) · Journal of Data Science · doi:10.6339/jds.202007_18(3).0020 · Cited by 5
Una hoja de ruta para la Vacuna COVID 19 en Colombia, un reto posible
Gómez‐Marín, J. E., Osório, J. C. C., Patarroyo, M. A., et al. (2020) · Infectio · doi:10.22354/in.v25i1.901 · Cited by 5
“Infectio 2020; 25(1): 7-10 Una vacuna para COVID 19 es una necesidad urgente de la comunidad global.”
Background
Prevalence of post-vaccine side effects among COVID-19 immunized community of Southern Pakistan
Qureshi, A., Sulaiman, S. A. S., Rehman, W., Mehmood, A., Idrees, S., & Kumar, N. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285736 · Cited by 7
A Human-Immune-System (HIS) humanized mouse model (DRAGA: HLA-A2. HLA-DR4. Rag1 KO.IL-2Rγc KO. NOD) for COVID-19Preprint
Brumeanu, T.-D., Vir, P., Karim, A. F., Kar, S., Benetiene, D., Lok, M., Greenhouse, J., Putmon-Taylor, T., Kitajewski, C., Chung, K., et al. (2020) · bioRxiv · doi:10.1101/2020.08.19.251249 · Cited by 13
Treatments and a vaccine for COVID-19: The need for coordinating policies on R&D, manufacturing and access
OECD (2020) · OECD policy responses to coronavirus (Covid-19) · doi:10.1787/6e7669a9-en · Cited by 5
Air Pollution, SARS-CoV-2 and the Wider Implications - An Overview of Recent Events with a Focus on Italy
Madl, P., Arvay, C. G., Gatti, A. M., Giuliani, L., & Lettner, H. (2021) · Aerosol and Air Quality Research · doi:10.4209/aaqr.200438 · Cited by 4
“Critics of genetic vaccines therefore point out that any shortenings of clinical evaluations for the development of a vaccine against COVID-19, especially when based on the transduction of nucleic acids, would be a violation of the precautionary principle (Arvay, 2020; Jiang, 2020).”
What we have learned from the COVID-19 pandemic: Time to think outside the box, maybe far outside
Lambert, W. C., Alhatem, A., Lambert, M. W., et al. (2020) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2020.12.020 · Cited by 4
A Case of Neuroleptic Malignant Syndrome After COVID-19 Vaccination and Possible Mechanisms of Vaccines in the Formation of This Syndrome
Taşçı, İ., & Uğur, K. (2022) · Psychiatry and Clinical Psychopharmacology · doi:10.5152/pcp.2022.21288 · Cited by 4
COVID-19 Vaccines:A Race Against Time in the Middle of Death and Devastation!Preprint
Khuroo, M. S., Khuroo, M. S., Khuroo, M. S., Sofi, A. A., & Khuroo, N. (2020) · Preprints.org · doi:10.20944/preprints202005.0223.v1 · Cited by 4
Infection-Simulator, Immunostimulatory and Immunomodulatory Effects of Interferons I and III in Biological Systems: A New Era in Vaccinology and Therapeutics Possible?Preprint
Carp, T.-N., Metoudi, M., & Ojha, V. (2024) · Preprints.org · doi:10.20944/preprints202212.0155.v6 · Cited by 4
Psychological and Personality Characteristics Associated With COVID-19 Vaccination Behavior in Korean General Population
Ryu, S., Kim, J., Lee, J., Kang, Y.-S., Shin, H., Jung, S., Kim, J., & Kim, S. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e234 · Cited by 3
Genetische Impfstoffe gegen COVID-19: Hoffnung oder Risiko
Arvay, C. G. (2020) · Bulletin des Médecins Suisses · doi:10.4414/bms.2020.18982 · Cited by 3
COVID-19: Lesson Learnt from Diagnostics to Therapeutics
Panda, P. K., Chavda, V. P., Neve, K., Mishra, S., Verma, S. K., & Ahuja, R. (2022) · Springer eBooks · doi:10.1007/978-981-19-3979-2_16 · Cited by 4
COVID-19;-The origin, genetics,and management of the infection of mothers and babies
El‐Sayyad, H. I., & Abdalhafid, Y. K. A. (2020) · Egyptian Journal of Basic and Applied Sciences · doi:10.1080/2314808x.2020.1843119 · Cited by 3
SARS-CoV-2 mass vaccination: Urgent questions on vaccine safety that demand answers from international health agencies, regulatory authorities, governments and vaccine developersPreprint
Bruno, R., McCullough, P. A., Vila, T. F. I., Henrion‐Caude, A., García-Gasca, T., Zaitzeva, G. P., Priester, S., Albarracín, M. J. M., Sousa‐Escandón, A., Mirones, F. L., et al. (2021) · doi:10.22541/au.162136772.22862058/v1 · Cited by 3
SARS-CoV-2 Vaccine
Walker, K. A. B. (2020) · Global Reproductive Health · doi:10.1097/grh.0000000000000042 · Cited by 3
On vous aime beaucoup, mais repassez une autre fois
Renaud, L. (2020) · Téoros Revue de recherche en tourisme · doi:10.7202/1074909ar · Cited by 2
Synthetic and Semi-synthetic Drugs as a Promising Therapeutic Option for the Treatment of COVID-19
Shirbhate, E., Patel, P., Patel, V. K., Veerasamy, R., Sharma, P. C., Sinha, B. N., & Rajak, H. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666201204162103 · Cited by 2
SARS-CoV-2 mass vaccination: Urgent questions on vaccine safety that demand answers from international health agencies, regulatory authorities, governments and vaccine developersPreprint
Bruno, R., McCullough, P. A., Vila, T. F. I., Henrion‐Caude, A., García-Gasca, T., Zaitzeva, G. P., Priester, S., Albarracín, M. J. M., Sousa‐Escandón, A., Mirones, F. L., et al. (2021) · doi:10.22541/au.162136772.22862058/v2 · Cited by 2
Low-Dose Interferon I and III-Based Nasal Sprays: A Good-Looking COVID-19 Vaccine Candidate?Preprint
Carp, T.-N., & Metoudi, M. (2022) · Preprints.org · doi:10.20944/preprints202212.0155.v2 · Cited by 1
Low-Dose Interferon I and III-Based Nasal Sprays: A Good-Looking COVID-19 Vaccine Candidate and a Therapy of the Future?Preprint
Carp, T.-N., Metoudi, M., Brown, B., & Ojha, V. (2023) · Preprints.org · doi:10.20944/preprints202212.0155.v4 · Cited by 2
Fish Blood Cell as Biological Dosimeter: In Between Measurements, Radiomics, Preprocessing, and Artificial Intelligence
Felicetti, F., Carnì, D. L., & Lamonaca, F. (2024) · Lecture notes in networks and systems · doi:10.1007/978-981-97-6992-6_4 · Cited by 1
Exploring Public Sentiment on the Repurposing of Ivermectin for COVID-19 Treatment: Cross-Sectional Study Using Twitter Data
Kautsar, A. P., Sinuraya, R. K., van der Schans, J., Postma, M. J., & Suwantika, A. A. (2025) · JMIR Formative Research · doi:10.2196/50536 · Cited by 1
“As the COVID-19 pandemic evolves, the scientific community confronts the limitations of vaccines due to emerging viral mutations that potentially decrease vaccine efficacy [1], thus necessitating a parallel investigation into additional therapeutic agents.”
The Increasing Number of Infected in Victoria, Australia since June 15, 2020, is the Result of Over-Testing and Over-Controlling without Safety
Boretti, A. A. (2020) · Integrative Journal of Medical Sciences · doi:10.15342/ijms.7.187 · Cited by 1
“Express coronavirus vaccines are unnecessary or even dangerous ([40]).”
Background
Estimating global case fatality rate of coronavirus disease 2019 (COVID-19) pandemic
Manisha, M., & Shyamapada, M. (2020) · International Journal of Clinical Microbiology and Biochemical Technology · doi:10.29328/journal.ijcmbt.1001014 · Cited by 1
El Hombre bajo la apariencia del Homo tecnologicus en el contexto del COVID-19 en Perú
Osores, R. I. V., Jiménez, O. C. S., Herrera, T. A. L., ORUÉ, L. A. M., & Duarez, M. F. G. (2020) · Alpha Centauri · doi:10.47422/ac.v1i1.4 · Cited by 1
“…a las nuevas tecnologías (Vertiz-Osores et al. 2020), llegando a su expresión máxima de comunicarse continuamente y buscando alternativas que solucionen el problema de inmediato (Abd El-Aziz & Stockand, 2020; Fauci, Lane, & Redfield, 2020; Jiang, 2020) y se retomen las actividades de nuevo.”
Background
A Risk-Based Screening Approach to Patients Needing Surgery During the De-Escalation Phase of COVID-19 Pandemic
Vilallonga, R., Pellino, G., Almirante, B., González, J. M. D., Blanco‐Colino, R., Petrola, C., & Armengol, M. (2020) · Surgical Innovation · doi:10.1177/1553350620975886 · Cited by 1
COVID-19 vaccine: Potential candidates, achievements, and challenges
Shoaib, M., Waheed, A., Wajid, M., Urwa, H., Khan, T. S., Khan, M. S., Aslam, M. W., Ahmad, S., Jafar, K., Akmal, H., et al. (2021) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2021.15.3.0145 · Cited by 1
“With many uncertainties, rapid mass production is also a big challenge to overcome the demand for vaccines against an epidemic disease [43].”
Background
COVID-19 Management, Treatment and Vaccination Strategies as the Most Efficient Host Manipulation by SARS CoV-2: Reappraisal of a Serious Global Public Health Crisis
Tripathy, A., & Pradhan, R. K. (2021) · Indian Journal of Public Health Research & Development · doi:10.37506/ijphrd.v13i1.17324 · Cited by 1
“Antibody-induced enhancement is a well known phenomenon in pathogen mutations in response to vaccines[21-23].”
Background
3β-Acetoxy-21α-H-hop-22(29)ene, a novel multitargeted phytocompound against SARS-CoV-2: in silico screening
Siddique, S., & Kumar, R. P. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2058094 · Cited by 1
“The SARS-CoV-2 mutates faster and therefore previously effective antivirals might become ineffective (Jiang, 2020).”
Background
Current strategies and future perspectives in COVID-19 therapy
Aravind, S. R., Mathew, K. A., Madathil, B. K., Mini, S., & John, A. P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89972-7.00011-8 · Cited by 1
The Recent Updates on Neoteric Variants of Covid-19 Virus and Therapeutic Effectiveness of Vaccines against the Variants.
Chaudhary, S., El‐Shorbagi, A., Chaudhary, A., Agarwal, G., Tripathi, P. N., & Dumoga, S. (2022) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2456 · Cited by 1
“Cell Host Microbe; 29(3):477-488 (2021).”
Rlip Protein: A Potential Target for COVID-19
Kopel, J. J., Singh, S. P., Hindle, A., Quirch, M., Bose, C., & Awasthi, S. (2022) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.55729/2000-9666.1090 · Cited by 1
Distinct evolution of infection-enhancing and neutralizing epitopes in the spike protein of SARS-CoV-2 variants (from alpha to omicron) : a structural and molecular epidemiology studyPreprint
GUERIN, P., Yahi, N., Azzaz, F., Chahinian, H., Sabatier, J., & Fantini, J. (2021) · Research Square · doi:10.21203/rs.3.rs-1054360/v2 · Cited by 1
“A similar warning on vaccine safety due to potential risks of ADE was independently published by Shibo Jiang [18].”
Background
COVID-19 và thế giới xuất bản học thuậtPreprint
Ho, M. (2020) · doi:10.31219/osf.io/b69eh · Cited by 1
“Đối mặt với những trắc trở giữa mùa dịch, các tiếng nói tiên phong đến từ Nature hay Science trở thành kim chỉ nam quan trọng cho cộng đồng khoa học.”
References
Engebretsen, E., & Baker, M. (2022) · Cambridge University Press eBooks · doi:10.1017/9781009030687.007
Low-Dose Interferon I and Iii-Based Nasal Sprays: A Good-Looking Covid-19 Vaccine Candidate?Preprint
Carp, T.-N., & Metoudi, M. (2022) · Preprints.org · doi:10.20944/preprints202212.0155.v1
Low-Dose Interferon I and III-Based Nasal Sprays: A Good-Looking COVID-19 Vaccine Candidate?Preprint
Carp, T.-N., Metoudi, M., Brown, B., & Ojha, V. (2023) · Preprints.org · doi:10.20944/preprints202212.0155.v3
Governance in Crisis: Institutionalizing Reflective Report to Guide Decision Making Under UncertaintyPreprint
Starominski-Uehara, M. (2020) · doi:10.31235/osf.io/y3nsa
COVID-19; An Update on the Novel Coronavirus SARS-CoV-2 Pandemic
Chakravorty, S. (2020) · Sushruta Journal of Health Policy & Opinions · doi:10.38192/13.1.1
Immunological Defence beyond Vaccination- A Review
Ping-Chung, L., Chung-lap, B. C., & Chun-kwok, W. (2020) · Journal of Vaccines and Immunology · doi:10.17352/jvi.000031
“By now we should understand that our COVID-19 vaccine has many hurdles to go through in the subsequent months [6,7].”
Background
A brief review of the latest pharmacological treatments of COVID-19.
Eftekhar, S. P., Kazemi, S., & Moghadamnia, A. A. (2020) · PubMed · doi:10.22088/cjim.11.0.460
“Vaccine safety is an important issue, and vaccines should not be produced without regard to safety (22).”
Background
No Scientific Clinical Evidence for long term Safety of Newly Evolved COVID_19 Vaccines: Review and Meta-analysis.
Helmy, Y. (2020) · Al-Azhar International Medical Journal /Al-Azhar International Medical Journal · doi:10.21608/aimj.2020.55247.1382
Potential pharmacological and non-pharmacological interventions for coronavirus disease 2019 (COVID-19): A Narrative Review.
Arif, T. B., Saquib, J., Iqbal, A., et al. (2021) · The Professional Medical Journal · doi:10.29309/tpmj/2021.28.04.6010
Spectrum of COVID-19: A Disorder of Multisystem Beyond Respiratory Disease
Luo, J. J., & Dun, N. J. (2020) · Journal of Neurology and Experimental Neuroscience · doi:10.17756/jnen.2020-s1-004
“Thus, it has been cautioned that hasty development of such vaccines may be risky [108].”
Background
Challenges and Progress in Vaccine Development for COVID-19 Coronavirus (SARS-CoV-2): A Review
Moharir, K. S., Arora, S., Yende, S. R., Lohiya, G. K., & Shah, S. (2021) · The Open COVID Journal · doi:10.2174/2666958702101010065
COVID-19: Vaccines on Their Marks
Jagtiani, E., & Vithlani, D. (2021) · The Bombay Technologist · doi:10.36664/bt/2021/v68i1/162888
Distinct evolution of infection-enhancing and neutralizing epitopes in the spike protein of SARS-CoV-2 variants (alpha, beta, gamma, delta, lambda and mu) : a structural and molecular epidemiology studyPreprint
GUERIN, P., Yahi, N., Azzaz, F., Chahinian, H., Sabatier, J., & Fantini, J. (2021) · Research Square · doi:10.21203/rs.3.rs-1054360/v1
“A similar warning on vaccine safety due to potential risks of ADE was independently published by Shibo Jiang [18].”
Background
A Comprehensive Review: Prevention and Control of SARS Co-V-2
Chauhan, P., Katiyar, P., Kalpana, K., Verma, S. K., Parveen, A., & Yadav, R. K. (2022) · Acta Scientific Pharmaceutical Sciences · doi:10.31080/asps.2022.06.0835
新型コロナウイルス感染症の治療方法とワクチン: 研究開発、製造、使用に関する政策調整の必要性
OECD (2020) · Singata korona wairusu (Covid-19) he no OECD seisaku tai'ō · doi:10.1787/01dc92e8-ja
An overview of possible solutions putting an end to the COVID-19 pandemic.
Afkham, S. A., Hessami, A., Saghazadeh, A., & Rezaei, N. (2022) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v93i2.12130 · Cited by 1
A review of health security and vaccine diplomacy during COVID-19 pandemic
Moorthy, R., & Naidu, L. (2022) · International Journal of Public Health Science (IJPHS) · doi:10.11591/ijphs.v11i2.21363
Design and assembly of plant-based COVID-19 candidate vaccines: reсent development and future prospects
Uvarova, E. A., Belavin, P. A., & Дейнеко, Е. В. (2022) · Vavilov Journal of Genetics and Breeding · doi:10.18699/vjgb-22-39
“However, the use of new vaccines for the prevention of the population is dictated by the need for a deep assessment of their effectiveness and impact on the human body, as well as the possibilities for their industrial development (Jiang, 2020).”
Background
Safety Standard Tenaga Kesehatan dan Mahasiswa PKL dalam Pencegahan Penularaan COVID-19 di RS X
Nuraininabilah, F., & Sonia, D. (2021) · Cerdika Jurnal Ilmiah Indonesia · doi:10.36418/cerdika.v1i12.260
The role of pharmacovigilance in patient safety in the COVID-19 pandemic
Primo, F. T., Araújo, G. D. M. S., Primo, L. S., et al. (2022) · VITTALLE - Revista de Ciências da Saúde · doi:10.14295/vittalle.v34i1.14121
“However, in times of urgency like this, the all-or-nothing relationship is imposed on both patients and health professionals, since, when in doubt between providing treatment to the patient and suffering from AE or leaving it to its own capacity, the first option is the one that has prevailed (33).”
Background
Virtual Screening of Shuanghuanglian Components for the Binding to the Proteinases of SARS-CoV-2
Yang, Y., Ainiwaer, D., Wang, X., et al. (2022) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2022.00061
Rethinking the role of tourism in modern society through the lenses of the public and general wellbeing
Wen, J., Nunkoo, R., & Kozak, M. (2022) · Edward Elgar Publishing eBooks · doi:10.4337/9781800378308.00007
Need and Possibilities of Phytocompounds against SARS-CoV-2: Recent Advances in COVID-19 Therapy
Kumar, R. P. (2023) · Current Traditional Medicine · doi:10.2174/2215083809666230221151814
Case Study: COVID-19 Vaccine Development
Siewert, S., Kieslich, K., Braun, M., et al. (2023) · SpringerBriefs in philosophy · doi:10.1007/978-3-031-16004-2_6
Influencing factors of COVID-19 vaccination hesitancy among adults in Taiwan, China: a cross-sectional studyPreprint
Huang, C.-L., Chen, J., Chen, X., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2845365/v1
Current Trends in the Development of Vaccines from Micro to Industrial Level
Khan, Y., Maalik, A., Hakeemullah, Sattar, A., Mazhar, D., Hashmi, M. Z., Bibi, M., Aslam, S., Aminullah, S., & Ahmed, B. (2024) · Springer eBooks · doi:10.1007/978-3-031-50989-6_14
Additional file 1 of Pathophysiology and treatment strategies for COVID-19
Kumar, M., & Al Khodor, S. (2020) · Figshare · doi:10.6084/m9.figshare.12960345

Authors: Jiang, S.
Affiliations: Shanghai Medical College of Fudan University (CN)
Corresponding author: Jiang, Shibo
ORCID: Jiang, Shibo
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2020-03-16
Volume: 579
Issue: 7799
Pages: 321-321
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/d41586-020-00751-9
OpenAlex: W3011324254
Cited by: 174
References: 0
Citations by year: 2025: 2 · 2024: 5 · 2023: 10 · 2022: 28 · 2021: 42 · 2020: 86
FWCI: 5.45
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Legal, Health, Environmental and COVID-19 Challenges
Social Sciences › Health › Vaccine Coverage and Hesitancy
Keywords: COVID-19 pandemic, vaccine rollout, drug development, drug safety, safety guarantees, pandemic response
MeSH terms: Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Vaccines, COVID-19 Drug Treatment, China, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Immunity, Pneumonia, Viral, Viral Vaccines, Coronavirus Infections, Models, Animal, Severe Acute Respiratory Syndrome, Severe acute respiratory syndrome-related coronavirus, Patient Safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks